Literature DB >> 6924928

Inhibition of zymosan-induced alternative complement pathway activation by concanavalin A.

M C Smith, J Pensky, G B Naff.   

Abstract

Zymosan, a polysaccharide composed primarily of glucan and mannan residues, activates the complement system through the alternative complement pathway. We showed that zymosan-induced complement activation is inhibited by zymosan-bound lectins with carbohydrate specificities for mannosyl and glycosyl residues. Lectins unable to bind mannosyl or glucosyl residues did not inhibit zymosan-induced complement activation.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6924928      PMCID： PMC347886          DOI： 10.1128/iai.38.3.1279-1284.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  21 in total

1.  On the composition of zymosan.

Authors:  F J DI CARLO; J V FIORE
Journal:  Science       Date:  1958-04-04       Impact factor: 47.728

2.  The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena.

Authors:  L PILLEMER; L BLUM; I H LEPOW; O A ROSS; E W TODD; A C WARDLAW
Journal:  Science       Date:  1954-08-20       Impact factor: 47.728

3.  Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins.

Authors:  R D Schreiber; M K Pangburn; P H Lesavre; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

4.  Complement utilization by guinea pig 1 and 2-immunoglobulins through the C3 activator system.

Authors:  A L Sandberg; O Götze; H J Müller-Eberhard; A G Osler
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

5.  Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b.

Authors:  M D Kazatchkine; D T Fearon; K F Austen
Journal:  J Immunol       Date:  1979-01       Impact factor: 5.422

6.  Activation of the alternative complement pathway: recognition of surface structures on activators by bound C3b.

Authors:  M K Pangburn; D C Morrison; R D Schreiber; H J Müller-Eberhard
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

7.  Effect of concanavalin A on the hemolytic activity of the components of the classical complement pathway.

Authors:  A P Gee; M D Boyle; J J Langone
Journal:  Mol Immunol       Date:  1980-01       Impact factor: 4.407

8.  Protein-carbohydrate interaction. IX. Application of the quantitative hapten inhibition technique to polysaccharide-concanavalin A interaction. Some comments on the forces involved n concanavalin A-polysaccharide interaction.

Authors:  L L So; I J Goldstein
Journal:  J Immunol       Date:  1967-07       Impact factor: 5.422

9.  The properdin system and immunity. V. The bactericidal activity of the properdin system.

Authors:  A C WARDLAW; L PILLEMER
Journal:  J Exp Med       Date:  1956-05-01       Impact factor: 14.307

10.  Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.

Authors:  D T Fearon; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205
View more
  3 in total

1.  Upregulation and release of soluble fms-like tyrosine kinase receptor 1 mediated by complement activation in human syncytiotrophoblast cells.

Authors:  Manu Banadakoppa; Meena Balakrishnan; Chandra Yallampalli
Journal:  Am J Reprod Immunol       Date:  2018-08-12       Impact factor: 3.886

2.  Interleukin-1β and cathepsin D modulate formation of the terminal complement complex in cultured human disc tissue.

Authors:  Graciosa Q Teixeira; Zhiyao Yong; Amelie Kuhn; Jana Riegger; Raquel M Goncalves; Michael Ruf; Uwe M Mauer; Markus Huber-Lang; Anita Ignatius; Rolf E Brenner; Cornelia Neidlinger-Wilke
Journal:  Eur Spine J       Date:  2021-06-24       Impact factor: 3.134

3.  Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission.

Authors:  E B Volokhina; D Westra; T J A M van der Velden; N C A J van de Kar; T E Mollnes; L P van den Heuvel
Journal:  Clin Exp Immunol       Date:  2015-08       Impact factor: 4.330
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.